Share This Article:

The Role of Lactic Acid Bacteria in the Pathophysiology and Treatment of Irritable Bowel Syndrome (IBS)

Abstract Full-Text HTML Download Download as PDF (Size:244KB) PP. 27-39
DOI: 10.4236/fns.2013.411A005    5,529 Downloads   7,989 Views   Citations

ABSTRACT

Irritable bowel syndrome (IBS) is a multifactorial chronic disorder characterized by various abdominal complaints and a worldwide prevalence of 10% - 20%. Although its etiology and pathophysiology are complex and still not completely understood, aberrations along the microbe-gut-brain axis are known to play a central role. IBS is characterized by interrelated alterations in intestinal barrier function, gut microbe composition, immune activation, afferent sensory signaling and brain activity. Pharmaceutical treatment is generally ineffective and, hence, most therapeutic strategies are based on non-drug approaches. A promising option is the administration of probiotics, in which lactic acid bacteria strains are considered specifically beneficial. This review aims to provide a concise, although comprehensive, overview of the role of lactic acid bacteria in the pathophysiology and treatment of IBS.

Conflicts of Interest

The authors declare no conflicts of interest.

Cite this paper

J. König, I. Rangel and R. Brummer, "The Role of Lactic Acid Bacteria in the Pathophysiology and Treatment of Irritable Bowel Syndrome (IBS)," Food and Nutrition Sciences, Vol. 4 No. 11A, 2013, pp. 27-39. doi: 10.4236/fns.2013.411A005.

References

[1] H. B. El-Serag, K. Olden and D. Bjorkman, “HealthRelated Quality of Life among Persons with Irritable Bowel Syndrome: A Systematic Review,” Alimentary Pharmacology & Therapeutics, Vol. 16, No. 6, 2002, pp. 1171-1185. http://dx.doi.org/10.1046/j.1365-2036.2002.01290.x
[2] R. S. Sandler, J. E. Everhart, M. Donowitz, E. Adams, K. Cronin, C. Goodman, E. Gemmen, S. Shah, A. Avdic and R. Rubin, “The Burden of Selected Digestive Diseases in the United States,” Gastroenterology, Vol. 122, No. 5, 2002, pp. 1500-1511.
http://dx.doi.org/10.1053/gast.2002.32978
[3] G. F. Longstreth, W. G. Thompson, W. D. Chey, L. A. Houghton, F. Mearin and R. C. Spiller, “Functional Bowel Disorders,” Gastroenterology, Vol. 130, No. 5, 2006, pp. 1480-1491.
http://dx.doi.org/10.1053/j.gastro.2005.11.061
[4] T. Karantanos, T. Markoutsaki, M. Gazouli, N. P. Anagnou and D. G. Karamanolis, “Current Insights into the Pathophysiology of Irritable Bowel Syndrome,” Gut Pathogens, Vol. 2, No. 3, 2010, pp. 3-4749-2-3.
[5] G. Barbara, C. Cremon, G. Carini, L. Bellacosa, L. Zecchi, R. De Giorgio, R. Corinaldesi and V. Stanghellini, “The Immune System in Irritable Bowel Syndrome,” Journal of Neurogastroenterology and Motility, Vol. 17, No. 4, 2011, pp. 349-359.
http://dx.doi.org/10.5056/jnm.2011.17.4.349
[6] S. C. Bischoff, “Physiological and Pathophysiological Functions of Intestinal Mast Cells,” Seminars in Immunopathology, Vol. 31, No. 2, 2009, pp. 185-205.
http://dx.doi.org/10.1007/s00281-009-0165-4
[7] V. S. Chadwick, W. Chen, D. Shu, B. Paulus, P. Bethwaite, A. Tie and I. Wilson, “Activation of the Mucosal Immune System in Irritable Bowel Syndrome,” Gastroenterology, Vol. 122, No. 7, 2002, pp. 1778-1783.
http://dx.doi.org/10.1053/gast.2002.33579
[8] C. Cremon, L. Gargano, A. M. Morselli-Labate, D. Santini, R. F. Cogliandro, R. De Giorgio, V. Stanghellini, R. Corinaldesi and G. Barbara, “Mucosal Immune Activation in Irritable Bowel Syndrome: Gender-Dependence and Association with Digestive Symptoms,” The American Journal of Gastroenterology, Vol. 104, No. 2, 2009, pp. 392-400. http://dx.doi.org/10.1038/ajg.2008.94
[9] J. Fichna and M. A. Storr, “Brain-Gut Interactions in IBS,” Frontiers in Pharmacology, Vol. 3, 2012, p. 127.
http://dx.doi.org/10.3389/fphar.2012.00127
[10] A. Salonen, W. M. de Vos and A. Palva, “Gastrointestinal Microbiota in Irritable Bowel Syndrome: Present State and Perspectives,” Microbiology, Vol. 156, No. 11, 2010, pp. 3205-3215. http://dx.doi.org/10.1099/mic.0.043257-0
[11] M. Simren, G. Barbara, H. J. Flint, B. M. Spiegel, R. C. Spiller, S. Vanner, E. F. Verdu, P. J. Whorwell, E. G. Zoetendal and Rome Foundation Committee, “Intestinal Microbiota in Functional Bowel Disorders: A Rome Foundation Report,” Gut, Vol. 62, No. 1, 2013, pp. 159176. http://dx.doi.org/10.1136/gutjnl-2012-302167
[12] R. Spiller and C. Lam, “An Update on Post-Infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome,” Journal of Neurogastroenterology and Motility, Vol. 18, No. 3, 2012, pp. 258-268.
http://dx.doi.org/10.5056/jnm.2012.18.3.258
[13] K. Kajander, E. Myllyluoma, M. Rajilic-Stojanovic, S. Kyronpalo, M. Rasmussen, S. Jarvenpaa, E. G. Zoetendal, W. M. de Vos, H. Vapaatalo and R. Korpela, “Clinical Trial: Multispecies Probiotic Supplementation Alleviates the Symptoms of Irritable Bowel Syndrome and Stabilizes Intestinal Microbiota,” Alimentary Pharmacology & Therapeutics, Vol. 27, No. 1, 2008, pp. 48-57.
http://dx.doi.org/10.1111/j.1365-2036.2007.03542.x
[14] R. Spiller, “Review Article: Probiotics and Prebiotics in Irritable Bowel Syndrome,” Alimentary Pharmacology & Therapeutics, Vol. 28, No. 4, 2008, pp. 385-396.
http://dx.doi.org/10.1111/j.1365-2036.2008.03750.x
[15] A. H. Sachdev and M. Pimentel, “Antibiotics for Irritable Bowel Syndrome: Rationale and Current Evidence,” Current Gastroenterology Reports, Vol. 14, No. 5, 2012, pp. 439-445. http://dx.doi.org/10.1007/s11894-012-0284-2
[16] A. Balsari, A. Ceccarelli, F. Dubini, E. Fesce and G. Poli, “The Fecal Microbial Population in the Irritable Bowel Syndrome,” Microbiologica, Vol. 5, No. 3, 1982, pp. 185-194.
[17] J. M. Si, Y. C. Yu, Y. J. Fan and S. J. Chen, “Intestinal Microecology and Quality of Life in Irritable Bowel Syndrome Patients,” World Journal of Gastroenterology, Vol. 10, No. 12, 2004, pp. 1802-1805.
[18] C. Tana, Y. Umesaki, A. Imaoka, T. Handa, M. Kanazawa and S. Fukudo, “Altered Profiles of Intestinal Microbiota and Organic Acids May Be the Origin of Symptoms in Irritable Bowel Syndrome,” Neurogastroenterology and Motility, Vol. 22, No. 5, 2010, pp. 512-9,e114e115.
[19] I. M. Carroll, Y. H. Chang, J. Park, R. B. Sartor and Y. Ringel, “Luminal and Mucosal-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome,” Gut Pathogens, Vol. 2, No. 1, 2010, pp. 19-4749-2-19.
[20] E. Malinen, T. Rinttila, K. Kajander, J. Matto, A. Kassinen, L. Krogius, M. Saarela, R. Korpela and A. Palva, “Analysis of the Fecal Microbiota of Irritable Bowel Syndrome Patients and Healthy Controls with Real-Time PCR,” The American Journal of Gastroenterology, Vol. 100, No. 2, 2005, pp. 373-382.
http://dx.doi.org/10.1111/j.1572-0241.2005.40312.x
[21] A. Kassinen, L. Krogius-Kurikka, H. Makivuokko, T. Rinttila, L. Paulin, J. Corander, E. Malinen, J. Apajalahti and A. Palva, “The Fecal Microbiota of Irritable Bowel Syndrome Patients Differs Significantly from That of Healthy Subjects,” Gastroenterology, Vol. 133, No. 1, 2007, pp. 24-33.
http://dx.doi.org/10.1053/j.gastro.2007.04.005
[22] M. Rajilic-Stojanovic, E. Biagi, H. G. Heilig, K. Kajander, R. A. Kekkonen, S. Tims and W. M. de Vos, “Global and Deep Molecular Analysis of Microbiota Signatures in Fecal Samples from Patients with Irritable Bowel Syndrome,” Gastroenterology, Vol. 141, No. 5, 2011, pp. 1792-1801. http://dx.doi.org/10.1053/j.gastro.2011.07.043
[23] I. B. Jeffery, P. W. O'Toole, L. Ohman, M. J. Claesson, J. Deane, E. M. Quigley and M. Simren, “An Irritable Bowel Syndrome Subtype Defined by Species-Specific Alterations in Faecal Microbiota,” Gut, Vol. 61, No. 7, 2012, pp. 997-1006.
http://dx.doi.org/10.1136/gutjnl-2011-301501
[24] I. M. Carroll, T. Ringel-Kulka, J. P. Siddle and Y. Ringel, “Alterations in Composition and Diversity of the Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome,” Neurogastroenterology and Motility, Vol. 24, No. 6, 2012, pp. 521-530,e248.
[25] E. G. Zoetendal, A. von Wright, T. Vilpponen-Salmela, K. Ben-Amor, A. D. Akkermans and W. M. de Vos, “Mucosa-Associated Bacteria in the Human Gastrointestinal Tract Are Uniformly Distributed along the Colon and Differ from the Community Recovered from Feces,” Applied and Environmental Microbiology, Vol. 68, No. 7, 2002, pp. 3401-3407.
http://dx.doi.org/10.1128/AEM.68.7.3401-3407.2002
[26] P. B. Eckburg, E. M. Bik, C. N. Bernstein, E. Purdom, L. Dethlefsen, M. Sargent, S. R. Gill, K. E. Nelson and D. A. Relman, “Diversity of the Human Intestinal Microbial Flora,” Science, Vol. 308, No. 5728, 2005, pp. 1635-1638.
http://dx.doi.org/10.1126/science.1110591
[27] I. M. Carroll, T. Ringel-Kulka, T. O. Keku, Y. H. Chang, C. D. Packey, R. B. Sartor and Y. Ringel, “Molecular Analysis of the LuminalAnd Mucosal-Associated Intestinal Microbiota in Diarrhea-Predominant Irritable Bowel Syndrome,” American Journal of Physiology, Gastrointestinal and Liver Physiology, Vol. 301, 2011, pp. G799G807. http://dx.doi.org/10.1152/ajpgi.00154.2011
[28] A. Swidsinski, J. Weber, V. Loening-Baucke, L. P. Hale and H. Lochs, “Spatial Organization and Composition of the Mucosal Flora in Patients with Inflammatory Bowel Disease,” Journal of Clinical Microbiology, Vol. 43, No. 7, 2005, pp. 3380-3389.
http://dx.doi.org/10.1128/JCM.43.7.3380-3389.2005
[29] G. C. Parkes, N. B. Rayment, B. N. Hudspith, L. Petrovska, M. C. Lomer, J. Brostoff, K. Whelan and J. D. Sanderson, “Distinct Microbial Populations Exist in the Mucosa-Associated Microbiota of Sub-Groups of Irritable Bowel Syndrome,” Neurogastroenterology and Motility, Vol. 24, No. 1, 2012, pp. 31-39.
http://dx.doi.org/10.1111/j.1365-2982.2011.01803.x
[30] A. P. Kerckhoffs, M. Samsom, M. E. van der Rest, J. de Vogel, J. Knol, K. Ben-Amor and L. M. Akkermans, “Lower Bifidobacteria Counts in Both Duodenal MucosaAssociated and Fecal Microbiota in Irritable Bowel Syndrome Patients,” World Journal of Gastroenterology, Vol. 15, No. 23, 2009, pp. 2887-2892.
http://dx.doi.org/10.3748/wjg.15.2887
[31] G. D. Wu, J. Chen, C. Hoffmann, K. Bittinger, Y. Y. Chen, S. A. Keilbaugh, M. Bewtra, D. Knights, W. A. Walters, R. Knight, R. Sinha, E. Gilroy, K. Gupta, R. Baldassano, L. Nessel, H. Li, F. D. Bushman and J. D. Lewis, “Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes,” Science, Vol. 334, No. 6052, 2011, pp. 105-108.
http://dx.doi.org/10.1126/science.1208344
[32] L. V. McFarland and S. Dublin, “Meta-Analysis of Probiotics for the Treatment of Irritable Bowel Syndrome,” World Journal of Gastroenterology, Vol. 14, No. 17, 2008, pp. 2650-2661.
http://dx.doi.org/10.3748/wjg.14.2650
[33] S. Nikfar, R. Rahimi, F. Rahimi, S. Derakhshani and M. Abdollahi, “Efficacy of Probiotics in Irritable Bowel Syndrome: A Meta-Analysis of Randomized, Controlled Trials,” Diseases of the Colon and Rectum, Vol. 51, No. 12, 2008, pp. 1775-1780.
http://dx.doi.org/10.1007/s10350-008-9335-z
[34] N. Hoveyda, C. Heneghan, K. R. Mahtani, R. Perera, N. Roberts and P. Glasziou, “A Systematic Review and Meta-Analysis: Probiotics in the Treatment of Irritable Bowel Syndrome,” BMC Gastroenterology, Vol. 9, No. 15, 2009, pp. 15-230X-9-15.
[35] G. Clarke, J. F. Cryan, T. G. Dinan and E. M. Quigley, “Review Article: Probiotics for the Treatment of Irritable Bowel Syndrome—Focus on Lactic Acid Bacteria,” Alimentary Pharmacology & Therapeutics, Vol. 35, No. 4, 2012, pp. 403-413.
http://dx.doi.org/10.1111/j.1365-2036.2011.04965.x
[36] S. C. Ligaarden, L. Axelsson, K. Naterstad, S. Lydersen and P. G. Farup, “A Candidate Probiotic with Unfavourable Effects in Subjects with Irritable Bowel Syndrome: A Randomised Controlled Trial,” BMC Gastroenterology, Vol. 10, No. 16, 2010.
[37] L. O’Mahony, J. McCarthy, P. Kelly, G. Hurley, F. Luo, K. Chen, G. C. O’Sullivan, B. Kiely, J. K. Collins, F. Shanahan and E. M. Quigley, “Lactobacillus and BifidoBacterium in Irritable Bowel Syndrome: Symptom Responses and Relationship to Cytokine Profiles,” Gastroenterology, Vol. 128, No. 3, 2005, pp. 541-551.
http://dx.doi.org/10.1053/j.gastro.2004.11.050
[38] P. J. Whorwell, L. Altringer, J. Morel, Y. Bond, D. Charbonneau, L. O’Mahony, B. Kiely, F. Shanahan and E. M. Quigley, “Efficacy of an Encapsulated Probiotic BifiDobacterium Infantis 35624 in Women with Irritable Bowel Syndrome,” The American Journal of Gastroenterology, Vol. 101, No. 7, 2006, pp. 1581-1590.
http://dx.doi.org/10.1111/j.1572-0241.2006.00734.x
[39] K. Kajander, K. Hatakka, T. Poussa, M. Farkkila and R. Korpela, “A Probiotic Mixture Alleviates Symptoms in Irritable Bowel Syndrome Patients: A Controlled 6Month Intervention,” Alimentary Pharmacology & Therapeutics, Vol. 22, No. 5, 2005, pp. 387-394.
http://dx.doi.org/10.1111/j.1365-2036.2005.02579.x
[40] K. Kajander, L. Krogius-Kurikka, T. Rinttila, H. Karjalainen, A. Palva and R. Korpela, “Effects of Multispecies Probiotic Supplementation on Intestinal Microbiota in Irritable Bowel Syndrome,” Alimentary Pharmacology & Therapeutics, Vol. 26, No. 3, 2007, pp. 463-473.
http://dx.doi.org/10.1111/j.1365-2036.2007.03391.x
[41] F. J. Troost, P. van Baarlen, P. Lindsey, A. Kodde, W. M. de Vos, M. Kleerebezem and R. J. Brummer, “Identification of the Transcriptional Response of Human Intestinal Mucosa to Lactobacillus Plantarum WCFS1 in Vivo,” BMC Genomics, Vol. 9, No. 374, 2008.
[42] P. van Baarlen, F. J. Troost, S. van Hemert, C. van der Meer, W. M. de Vos, P. J. de Groot, G. J. Hooiveld, R. J. Brummer and M. Kleerebezem, “Differential NF-KappaB Pathways Induction by Lactobacillus Plantarum in the Duodenum of Healthy Humans Correlating with Immune Tolerance,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 7, 2009, pp. 2371-2376.
http://dx.doi.org/10.1073/pnas.0809919106
[43] P. van Baarlen, F. Troost, C. van der Meer, G. Hooiveld, M. Boekschoten, R. J. Brummer and M. Kleerebezem, “Human Mucosal in Vivo Transcriptome Responses to Three Lactobacilli Indicate How Probiotics may Modu late Human Cellular Pathways,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, Suppl. 1, 2011, pp. 4562-4569.
http://dx.doi.org/10.1073/pnas.1000079107
[44] A. Lyra, L. Krogius-Kurikka, J. Nikkila, E. Malinen, K. Kajander, K. Kurikka, R. Korpela and A. Palva, “Effect of a Multispecies Probiotic Supplement on Quantity of Irritable bowel Syndrome-Related Intestinal Microbial Phylotypes,” BMC Gastroenterology, Vol. 10, No. 110, 2010.
[45] A. L. Servin, “Antagonistic Activities of Lactobacilli and Bifidobacteria against Microbial Pathogens,” FEMS Microbiology Reviews, Vol. 28, No. 4, 2004, pp. 405-440.
http://dx.doi.org/10.1016/j.femsre.2004.01.003
[46] A. Patel, N. Shah and J. B. Prajapati, “Clinical Appliance of Probiotics in the Treatment of Helicobacter pylori Infection—A Brief Review,” Journal of Microbiology, Immunology, and Infection, 2013, in press.
http://dx.doi.org/10.1016/j.jmii.2013.03.010
[47] S. Tejero-Sarinena, J. Barlow, A. Costabile, G. R. Gibson and I. Rowland, “In Vitro Evaluation of the Antimicrobial Activity of a Range of Probiotics against Pathogens: Evidence for the Effects of Organic Acids,” Anaerobe, Vol. 18, No. 5, 2012, pp. 530-538.
http://dx.doi.org/10.1016/j.anaerobe.2012.08.004
[48] P. Hutt, J. Shchepetova, K. Loivukene, T. Kullisaar and M. Mikelsaar, “Antagonistic Activity of Probiotic Lactobacilli and Bifidobacteria against Enteroand Uropatho0 gens,” Journal of Applied Microbiology, Vol. 100, No. 6, 2006, pp. 1324-1332.
http://dx.doi.org/10.1111/j.1365-2672.2006.02857.x
[49] K. Selle and T. R. Klaenhammer, “Genomic and Phenotypic Evidence for Probiotic Influences of Lactobacillus Gasseri on Human Health,” FEMS Microbiology Reviews, Vol. 37, No. 6, 2013, pp. 915-935.
[50] P. Kanmani, R. Satish Kumar, N. Yuvaraj, K. A. Paari, V. Pattukumar and V. Arul, “Probiotics and Its Functionally Valuable Products—A Review,” Critical Reviews in Food Science and Nutrition, Vol. 53, No. 6, 2013, pp. 641-658.
http://dx.doi.org/10.1080/10408398.2011.553752
[51] S. S. Awaisheh, A. A. Al-Nabulsi, T. M. Osaili, S. Ibrahim and R. Holley, “Inhibition of Cronobacter sakazakii by Heat Labile Bacteriocins Produced by Probiotic LAB Isolated from Healthy Infants,” Journal of Food Sciences, Vol. 78, No. 9, 2013, pp. M1416-M1420.
http://dx.doi.org/10.1111/1750-3841.12209
[52] J. K. Das, D. Mishra, P. Ray, P. Tripathy, T. K. Beuria, N. Singh and M. Suar, “In Vitro Evaluation of Anti-Infective Activity of a Lactobacillus plantarum Strain against Salmonella enterica Serovar Enteritidis,” Gut Pathogens, Vol. 5, No. 1, 2013, p. 11.
http://dx.doi.org/10.1186/1757-4749-5-11
[53] M. A. McGuckin, S. K. Linden, P. Sutton and T. H. Florin, “Mucin Dynamics and Enteric Pathogens,” Nature Reviews Microbioly, Vol. 9, No. 4, 2011, pp. 265-278.
[54] C. Martinez, A. Gonzalez-Castro, M. Vicario and J. Santos, “Cellular and Molecular Basis of Intestinal Barrier Dysfunction in the Irritable Bowel Syndrome,” Gut and Liver, Vol. 6, No. 3, 2012, pp. 305-315.
http://dx.doi.org/10.5009/gnl.2012.6.3.305
[55] A. E. Dorofeyev, E. A. Kiriyan, I. V. Vasilenko, O. A. Rassokhina and A. F. Elin, “Clinical, Endoscopical and Morphological Efficacy of Mesalazine in Patients with Irritable Bowel Syndrome,” Clinical and Experimental Gastroenteroly, Vol. 4, 2011, pp. 141-153.
[56] D. R. Mack, S. Michail, S. Wei, L. McDougall and M. A. Hollingsworth, “Probiotics Inhibit Enteropathogenic E. coli Adherence in Vitro by Inducing Intestinal Mucin Gene Expression,” American Journal of Physiology, Vol. 276, No. 4, 1999, pp. G941-G950.
[57] A. M. O’Hara and F. Shanahan, “Mechanisms of Action of Probiotics in Intestinal Diseases,” Scientific World Journal, Vol. 7, 2007, pp. 31-46.
http://dx.doi.org/10.1100/tsw.2007.26
[58] E. Gaudier, C. Michel, J. P. Segain, C. Cherbut and C. Hoebler, “The VSL# 3 Probiotic Mixture Modifies Microflora but Does not Heal Chronic Dextran-Sodium Sulfate-Induced Colitis or Reinforce the Mucus Barrier in Mice,” Journal of Nutrition, Vol. 135, No. 12, 2005, pp. 2753-2761.
[59] P. Dharmani, C. De Simone and K. Chadee, “The Probiotic Mixture VSL#3 Accelerates Gastric Ulcer Healing by Stimulating Vascular Endothelial Growth Factor,” PLoS ONE, Vol. 8, No. 3, 2013, Article ID: e58671.
http://dx.doi.org/10.1371/journal.pone.0058671
[60] C. Caballero-Franco, K. Keller, C. De Simone and K. Chadee, “The VSL#3 Probiotic Formula Induces Mucin Gene Expression and Secretion in Colonic Epithelial Cells,” American Journal of Physiology. Gastrointestinal and Liver Physiology, Vol. 292, No. 1, 2007, pp. G315G322.
http://dx.doi.org/10.1152/ajpgi.00265.2006
[61] J. M. Wells, “Immunomodulatory Mechanisms of Lactobacilli,” Microbial Cell Factories, Vol. 10, Suppl. 1, 2011, p. S17.
[62] J. Karczewski, F. J. Troost, I. Konings, J. Dekker, M. Kleerebezem, R. J. Brummer and J. M. Wells, “Regulation of Human Epithelial Tight Junction Proteins by Lactobacillus plantarum in Vivo and Protective Effects on the Epithelial Barrier,” American Journal of Physiology. Gastrointestinal and Liver Physiology, Vol. 298, No. 6, 2010, pp. G851-G859.
http://dx.doi.org/10.1152/ajpgi.00327.2009
[63] E. K. Brint, J. MacSharry, A. Fanning, F. Shanahan and E. M. Quigley, “Differential Expression of Toll-Like Receptors in Patients with Irritable Bowel Syndrome,” The American Journal of Gastroenterology, Vol. 106, No. 2, 2011, pp. 329-336.
[64] S. Ishihara, Y. Tada, N. Fukuba, A. Oka, R. Kusunoki, Y. Mishima, N. Oshima, I. Moriyama, T. Yuki, K. Kawashima and Y. Kinoshita, “Pathogenesis of Irritable Bowel Syndrome—Review Regarding Associated Infection and Immune Activation,” Digestion, Vol. 87, No. 3, 2013, pp. 204-211. http://dx.doi.org/10.1159/000350054
[65] A. C. Villani, M. Lemire, M. Thabane, A. Belisle, G. Geneau, A. X. Garg, W. F. Clark, P. Moayyedi, S. M. Collins, D. Franchimont and J. K. Marshall, “Genetic Risk Factors for Post-Infectious Irritable Bowel Syndrome Following a Waterborne Outbreak of Gastroenteritis,” Gastroenterology, Vol. 138, No. 4, 2010, pp. 1502-1513.
http://dx.doi.org/10.1053/j.gastro.2009.12.049
[66] C. Gomez-Llorente, S. Munoz and A. Gil, “Role of TollLike Receptors in the Development of Immunotolerance Mediated by Probiotics,” The Proceedings of the Nutrition Society, Vol. 69, No. 3, 2010, pp. 381-389.
http://dx.doi.org/10.1017/S0029665110001527
[67] Y. Hiramatsu, T. Satho, K. Irie, S. Shiimura, T. Okuno, T. Sharmin, S. Uyeda, Y. Fukumitsu, Y. Nakashima, F. Miake and N. Kashige, “Differences in TLR9-Dependent Inhibitory Effects of H2O2-Induced IL-8 Secretion and NF-Kappa B/I Kappa B-Alpha System Activation by Genomic DNA from Five Lactobacillus Species,” Microbes and Infection, Vol. 15, No. 2, 2013, pp. 96-104.
http://dx.doi.org/10.1016/j.micinf.2012.11.003
[68] M. Karlsson, N. Scherbak, G. Reid and J. Jass, “Lactobacillus rhamnosus GR-1 Enhances NF-kappaB Activation in Escherichia coli-Stimulated Urinary Bladder Cells Through TLR4,” BMC Microbiology, Vol. 12, No. 15, 2012.
[69] T. S. Plantinga, W. W. van Maren, J. van Bergenhenegouwen, M. Hameetman, S. Nierkens, C. Jacobs, D. J. de Jong, L. A. Joosten, B. van’t Land, J. Garssen, G. J. Adema and M. G. Netea, “Differential Toll-Like Receptor Recognition and Induction of Cytokine Profile by BifidoBacterium breve and Lactobacillus Strains of Probiotics,” Clinical and Vaccine Immunology, Vol. 18, No. 4, 2011, pp. 621-628.
http://dx.doi.org/10.1128/CVI.00498-10
[70] J. D. Wood, “Neuropathophysiology of Functional Gastrointestinal Disorders,” World Journal of Gastroenterology, Vol. 13, No. 9, 2007, pp. 1313-1332.
[71] Q. Zhou, B. Zhang and G. N. Verne, “Intestinal Membrane Permeability and Hypersensitivity in the Irritable Bowel Syndrome,” Pain, Vol. 146, No. 1, 2009, pp. 41-46.
http://dx.doi.org/10.1016/j.pain.2009.06.017
[72] R. Mennigen, K. Nolte, E. Rijcken, M. Utech, B. Loeffler, N. Senninger and M. Bruewer, “Probiotic Mixture VSL#3 Protects the Epithelial Barrier by Maintaining Tight Junction Protein Expression and Preventing Apoptosis in a Murine Model of Colitis,” American Journal of Physiology. Gastrointestinal and Liver Physiology, Vol. 296, No. 5, 2009, pp. G1140-1149.
http://dx.doi.org/10.1152/ajpgi.90534.2008
[73] E. Miyauchi, J. O’Callaghan, L. F. Butto, G. Hurley, S. Melgar, S. Tanabe, F. Shanahan, K. Nally and P. W. O’Toole, “Mechanism of Protection of Transepithelial Barrier Function by Lactobacillus salivarius: Strain Dependence and Attenuation by Bacteriocin Production,” American Journal of Physiology. Gastrointestinal and Liver Physiology, Vol. 303, No. 9, 2012, pp. G1029-G1041.
http://dx.doi.org/10.1152/ajpgi.00003.2012
[74] Y. K. Zhou, H. L. Qin, M. Zhang, T. Y. Shen, H. Q. Chen, Y. L. Ma, Z. X. Chu, P. Zhang and Z. H. Liu, “Effects of Lactobacillus plantarum on Gut Barrier Function in Experimental Obstructive Jaundice,” World Journal of Gastroenterology, Vol. 18, No. 30, 2012, pp. 3977-3991.
http://dx.doi.org/10.3748/wjg.v18.i30.3977
[75] M. T. Abreu, “Toll-Like Receptor Signalling in the Intestinal Epithelium: How Bacterial Recognition Shapes Intestinal Function,” Nature Reviews Immunology, Vol. 10, No. 2, 2010, pp. 131-144.
[76] C. B. Forsyth, A. Farhadi, S. M. Jakate, Y. Tang, M. Shaikh and A. Keshavarzian, “Lactobacillus GG Treatment Ameliorates Alcohol-Induced Intestinal Oxidative Stress, Gut Leakiness, and Liver Injury in a Rat Model of Alcoholic Steatohepatitis,” Alcohol, Vol. 43, No. 2, 2009, pp. 163-172.
http://dx.doi.org/10.1016/j.alcohol.2008.12.009
[77] G. Nardone, D. Compare, E. Liguori, V. Di Mauro, A. Rocco, M. Barone, A. Napoli, D. Lapi, M. R. Iovene and A. Colantuoni, “Protective Effects of Lactobacillus paracasei F19 in a Rat Model of Oxidative and Metabolic Hepatic Injury,” American Journal of Physiology. Gastrointestinal and Liver Physiology, Vol. 299, No. 3, 2010, pp. G669-G676. http://dx.doi.org/10.1152/ajpgi.00188.2010
[78] A. Amaretti, M. di Nunzio, A. Pompei, S. Raimondi, M. Rossi and A. Bordoni, “Antioxidant Properties of Potentially Probiotic Bacteria: In Vitro and in Vivo Activities,” Applied Microbiology and Biotechnology, Vol. 97, No. 2, 2013, pp. 809-817.
http://dx.doi.org/10.1007/s00253-012-4241-7
[79] N. Goyal, P. Rishi and G. Shukla, “Lactobacillus rhamnosus GG Antagonizes Giardia Intestinalis Induced Oxidative Stress and Intestinal Disaccharidases: An Experimental study,” World Journal of Microbiology & Biotechnology, Vol. 29, No. 6, 2013, pp. 1049-1057.
http://dx.doi.org/10.1007/s11274-013-1268-6
[80] J. F. Cryan and T. G. Dinan, “Mind-Altering Microorganisms: The Impact of the Gut Microbiota on Brain and Behaviour,” Nature Reviews. Neuroscience, Vol. 13, No. 10, 2012, pp. 701-712.
[81] J. A. Bravo, M. Julio-Pieper, P. Forsythe, W. Kunze, T. G. Dinan, J. Bienenstock and J. F. Cryan, “Communication between Gastrointestinal Bacteria and the Nervous System,” Current Opinion in Pharmacology, Vol. 12, No. 6, 2012, pp. 667-672.
http://dx.doi.org/10.1016/j.coph.2012.09.010
[82] P. Bercik, E. Denou, J. Collins, W. Jackson, J. Lu, J. Jury, Y. Deng, P. Blennerhassett, J. Macri, K. D. McCoy, E. F. Verdu and S. M. Collins, “The Intestinal Microbiota Affect Central Levels of Brain-Derived Neurotropic Factor and Behavior in Mice,” Gastroenterology, Vol. 141, No. 2, 2011, pp. 599-609.
[83] L. Desbonnet, L. Garrett, G. Clarke, B. Kiely, J. F. Cryan and T. G. Dinan, “Effects of the Probiotic Bifidobacterium infantis in the Maternal Separation Model of Depression,” Neuroscience, Vol. 170, No. 4, 2010, pp. 11791188.
http://dx.doi.org/10.1016/j.neuroscience.2010.08.005
[84] P. Bercik, A. J. Park, D. Sinclair, A. Khoshdel, J. Lu, X. Huang, Y. Deng, P. A. Blennerhassett, M. Fahnestock, D. Moine, B. Berger, J. D. Huizinga, W. Kunze, P. G. McLean, G. E. Bergonzelli, S. M. Collins and E. F. Verdu, “The Anxiolytic Effect of Bifidobacterium longum NCC3001 Involves Vagal Pathways for Gut-Brain Communication,” Neurogastroenterology and Motility, Vol. 23, No. 12, 2011, pp. 1132-1139.
http://dx.doi.org/10.1111/j.1365-2982.2011.01796.x
[85] J. A. Bravo, P. Forsythe, M. V. Chew, E. Escaravage, H. M. Savignac, T. G. Dinan, J. Bienenstock and J. F. Cryan, “Ingestion of Lactobacillus Strain Regulates Emotional Behavior and Central GABA Receptor Expression in a Mouse via the Vagus Nerve,” Proceedings of the National Academy of Sciences of the United States of America, Vol. 108, No. 38, 2011, pp. 16050-16055.
http://dx.doi.org/10.1073/pnas.1102999108
[86] M. Messaoudi, R. Lalonde, N. Violle, H. Javelot, D. Desor, A. Nejdi, J. F. Bisson, C. Rougeot, M. Pichelin, M. Cazaubiel and J. M. Cazaubiel, “Assessment of Psychotropic-Like Properties of a Probiotic Formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in Rats and Human Subjects,” The British Journal of Nutrition, Vol. 105, No. 5, 2011, pp. 755-764.
http://dx.doi.org/10.1017/S0007114510004319
[87] K. Tillisch, J. Labus, L. Kilpatrick, Z. Jiang, J. Stains, B. Ebrat, D. Guyonnet, S. Legrain-Raspaud, B. Trotin, B. Naliboff and E. A. Mayer, “Consumption of Fermented Milk Product with Probiotic Modulates Brain Activity,” Gastroenterology, Vol. 144, No. 7, 2013, pp. 1394-1401.
[88] D. Benton, C. Williams and A. Brown, “Impact of Consuming a Milk Drink Containing a Probiotic on Mood and Cognition,” European Journal of Clinical Nutrition, Vol. 61, No. 3, 2007, pp. 355-361.
http://dx.doi.org/10.1038/sj.ejcn.1602546
[89] A. V. Rao, A. C. Bested, T. M. Beaulne, M. A. Katzman, C. Iorio, J. M. Berardi and A. C. Logan, “A Randomized, Double-Blind, Placebo-Controlled Pilot Study of a Probiotic in Emotional Symptoms of Chronic Fatigue Syndrome,” Gut Pathogens, Vol. 1, No. 1, 2009, p. 6.
[90] C. Rousseaux, X. Thuru, A. Gelot, N. Barnich, C. Neut, L. Dubuquoy, C. Dubuquoy, E. Merour, K. Geboes, M. Chamaillard, A. Ouwehand, G. Leyer, D. Carcano, J. F. Colombel, D. Ardid and P. Desreumaux, “Lactobacillus acidophilus Modulates Intestinal Pain and Induces Opioid and Cannabinoid Receptors,” Nature Medicine, Vol. 13, No. 1, 2007, pp. 35-37.
[91] D. P. McKernan, P. Fitzgerald, T. G. Dinan and J. F. Cryan, “The Probiotic Bifidobacterium infantis 35624 Displays Visceral Antinociceptive Effects in the Rat,” Neurogastroenterology and Motility, Vol. 22, No. 9, 2010, pp. 1029-1035.
[92] E. G. Zoetendal, M. Rajilic-Stojanovic and W. M. de Vos, “High-Throughput Diversity and Functionality Analysis of the Gastrointestinal tract Microbiota,” Gut, Vol. 57, No. 11, 2008, pp. 1605-1615.
http://dx.doi.org/10.1136/gut.2007.133603
[93] J. Qin, R. Li, J. Raes, M. Arumugam, K. S. Burgdorf, C. Manichanh, T. Nielsen, N. Pons, F. Levenez, T. Yamada, D. R. Mende, J. Li, J. Xu, S. Li, D. Li, J. Cao, B. Wang, H. Liang, H. Zheng, Y. Xie, J. Tap, P. Lepage, M. Bertalan, J. M. Batto, T. Hansen, D. Le Paslier, A. Linneberg, H. B. Nielsen, E. Pelletier, P. Renault, T. Sicheritz-Ponten, K. Turner, H. Zhu, C. Yu, S. Li, M. Jian, Y. Zhou, Y. Li, X. Zhang, S. Li, N. Qin, H. Yang, J. Wang, S. Brunak, J. Dore, F. Guarner, K. Kristiansen, O. Pedersen, J. Parkhill, J. Weissenbach, P. Bork, S. D. Ehrlich and J. Wang, “A Human Gut Microbial Gene Catalogue Established by Metagenomic Sequencing,” Nature, Vol. 464, No. 7285, 2010, pp. 59-65.
http://dx.doi.org/10.1038/nature08821
[94] S. H. Duncan, P. Louis and H. J. Flint, “Lactate-utilizing Bacteria, Isolated from Human Feces, that Produce Butyrate as a Major Fermentation Product,” Applied and Environmental Microbiology, Vol. 70, No. 10, 2004, pp. 5810-5817.
http://dx.doi.org/10.1128/AEM.70.10.5810-5817.2004
[95] H. M. Hamer, D. Jonkers, K. Venema, S. Vanhoutvin, F. J. Troost and R. J. Brummer, “Review Article: The Role of Butyrate on Colonic Function,” Alimentary Pharmacology & Therapeutics, Vol. 27, No. 2, 2008, pp. 104-119.
http://dx.doi.org/10.1111/j.1365-2036.2007.03562.x
[96] H. M. Hamer, D. M. Jonkers, A. Bast, S. A. Vanhoutvin, M. A. Fischer, A. Kodde, F. J. Troost, K. Venema and R. J. Brummer, “Butyrate Modulates Oxidative Stress in the Colonic Mucosa of Healthy Humans,” Clinical Nutrition, Vol. 28, No. 1, 2009, pp. 88-93.
http://dx.doi.org/10.1016/j.clnu.2008.11.002
[97] H. M. Hamer, D. M. Jonkers, S. A. Vanhoutvin, F. J. Troost, G. Rijkers, A. de Bruine, A. Bast, K. Venema and R. J. Brummer, “Effect of Butyrate Enemas on Inflammation and Antioxidant Status in the Colonic Mucosa of Patients with Ulcerative Colitis in Remission,” Clinical Nutrition, Vol. 29, No. 6, 2010, pp. 738-744.
http://dx.doi.org/10.1016/j.clnu.2010.04.002
[98] S. A. Vanhoutvin, F. J. Troost, T. O. Kilkens, P. J. Lindsey, H. M. Hamer, D. M. Jonkers, K. Venema and R. J. Brummer, “The Effects of Butyrate Enemas on Visceral Perception in Healthy Volunteers,” Neurogastroenterology and Motility, Vol. 21, No. 9, 2009, pp. 952-976.
http://dx.doi.org/10.1111/j.1365-2982.2009.01324.x
[99] S. A. Vanhoutvin, F. J. Troost, H. M. Hamer, P. J. Lindsey, G. H. Koek, D. M. Jonkers, A. Kodde, K. Venema and R. J. Brummer, “Butyrate-Induced Transcriptional Changes in Human Colonic Mucosa,” PloS ONE, Vol. 4, No. 8, 2009, Article ID: e6759.
http://dx.doi.org/10.1371/journal.pone.0006759
[100] T. Banasiewicz, L. Krokowicz, Z. Stojcev, B. F. Kaczmarek, E. Kaczmarek, J. Maik, R. Marciniak, P. Krokowicz, J. Walkowiak and M. Drews, “Microencapsulated Sodium Butyrate Reduces the Frequency of Abdominal Pain in Patients with Irritable Bowel Syndrome,” Colorectal Disease, Vol. 15, No. 2, 2013, pp. 204-209.
http://dx.doi.org/10.1111/j.1463-1318.2012.03152.x
[101] S. Arboleya, N. Salazar, G. Solis, N. Fernandez, A. M. Hernandez-Barranco, I. Cuesta, M. Gueimonde and C. G. de los Reyes-Gavilan, “Assessment of Intestinal Microbiota Modulation Ability of Bifidobacterium Strains in In vitro Fecal Batch Cultures from Preterm Neonates,” Anaerobe, Vol. 19, 2013, pp. 9-16.
http://dx.doi.org/10.1016/j.anaerobe.2012.11.001
[102] K. P. Scott, S. W. Gratz, P. O. Sheridan, H. J. Flint and S. H. Duncan, “The Influence of Diet on the Gut Microbiota,” Pharmacological Research, Vol. 69, No. 1, 2013, pp. 52-60.
http://dx.doi.org/10.1016/j.phrs.2012.10.020
[103] M. C. Collado, J. Meriluoto and S. Salminen, “Development of New Probiotics by Strain Combinations: Is It Possible to Improve the Adhesion to Intestinal Mucus?” Journal of Dairy Science, Vol. 90, No. 6, 2007, pp. 27102716. http://dx.doi.org/10.3168/jds.2006-456
[104] M. Roberfroid, “Prebiotics: The Concept Revisited,” The Journal of Nutrition, Vol. 137, No. 3, 2007, pp. 830S837S.
[105] J. Tsuchiya, R. Barreto, R. Okura, S. Kawakita, E. Fesce and F. Marotta, “Single-Blind Follow-Up Study on the Effectiveness of a Symbiotic Preparation in Irritable Bowel Syndrome,” Chinese Journal of Digestive Diseases, Vol. 5, No. 4, 2004, pp. 169-174.
http://dx.doi.org/10.1111/j.1443-9573.2004.00176.x
[106] E. M. Quigley, “Prebiotics and Probiotics: Their Role in the Management of Gastrointestinal Disorders in Adults,” Nutrition in Clinical Practice: Official publication of the American Society for Parenteral and Enteral Nutrition, Vol. 27, No. 2, 2012, pp. 195-200.

  
comments powered by Disqus

Copyright © 2019 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.